Trial of Epinephrine and Albuterol in Bronchiolitis
Recruitment status was Active, not recruiting
The purpose of this study is to see which of the two most common drugs used to treat bronchiolitis works better. A child's participation in this study is expected to last less than 4 hours. Approximately 600 patients will be recruited to participate in this study at Kern Medical Center (KMC).
Bronchiolitis is a very common lung infection in babies. There are many drugs used to treat this disease but nobody knows which one, if any, works the best. Two of the most commonly used drugs are albuterol and epinephrine. These are both drugs given during breathing treatments with oxygen and a mask. We are doing this study to see which of these drugs works better or if they are both equally good. The study works as follows: after the consent process the baby gets three treatments.
- Nebulizer 1 (Treatment)
- Treatment + 30 minutes (approximately) Nebulizer 2
- Treatment + 60 minutes (approximately) Nebulizer 3
- Treatment + 120 minutes (approximately)
The baby will be reevaluated and either discharged home or revert to standard therapy. If the baby is discharged directly from the emergency department (E.D.), we will call you in three days time to see how he/she is doing.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Randomized Controlled Trial of Epinephrine and Albuterol in Bronchiolitis|
- Successful hospital discharge at three days
- Improvement in severity of disease score
- Improvement in respiratory status
|Study Start Date:||November 2003|
|Estimated Study Completion Date:||May 2006|
Double blind RCT. Primary outcome measure is admission defined as actual admission or discharge with unscheduled return leading to admission within 72 hours. Secondary endpoints include change in severity of illness and response of respiratory parameters to treatment.
|United States, California|
|Kern Medical Center|
|Bakersfield, California, United States, 93312|
|Principal Investigator:||Paul Walsh, Paul Walsh, MD MSc(peds)||Kern Medical Center, David Geffen School of Medicine, UCLA|
|Principal Investigator:||Paul Walsh||Research Director, Emergency Medicine|